Cited by 117Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration MechanismsNuclear Receptors and Signaling

Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease

Kurkowska-Jastrzębska, Iwona, Litwin, Tomasz, Joniec, Ilona, Ciesielska, Agnieszka, Przybyłkowski, Adam, Członkowski, Andrzej, Członkowska, Anna·2004·International Immunopharmacology

Abstract

The pathological process of neurodegeneration, which is observed in Alzheimer's (AD) and Parkinson's (PD) diseases and that follows any insult to the central nervous system, is accompanied by an inflammatory reaction, which is believed to contribute to the pathogenesis of the diseases. In accordance to this, the anti-inflammatory agents are suggested to be effective in slowing or inhibiting the degenerative process. In this study, we investigated the influence of dexamethasone (DXM) on the nigrostriatal dopaminergic neurons damage following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine (MPTP). Mice C57BL received pre-treatment of the various doses of dexamethasone followed by MPTP administration (40 mg/kg). We found that dexamethasone 1 mg/kg diminished a dopamine content depletion in striatum by about 20%, when the doses of 0.1 mg/kg was ineffective and 10 mg/kg even aggravate the dopamine content decrease. In the second step of the experiment, we chose the effective doses, 1 mg/kg, and started the treatment before and 24 h after MPTP administration. We observed the same protection in both situations: less dopamine depletion and less decrease in the number of dopaminergic cells in the substantia nigra (SN). Dexamethasone also similarly decreased the inflammatory reaction (glial activation, lymphocytic infiltration) in the injured areas. Our study showed that dexamethasone may exert a neuroprotective effect towards neurons injured by MPTP, but only when used in a proper dose. The mechanism of dexamethasone protective properties may be an inhibition of inflammatory process; however, direct interactions with neurons are also possible.

Integrity signals

Registry

Crossref · 10.1016/j.intimp.2004.05.006

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Alternative anti-inflammatory drugs including dexamethasone, minocycline, naloxone are being or have been tested in preclinical and clinical trials for PD.

    “Alternative drugs with anti-inflammatory properties, including dexamethasone, minocycline, naloxone, are going to be or have already been tested in preclinical and clinical trials.560–562”

    From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [561]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kurkowska-Jastrzębska, I., Litwin, T., Joniec, I., Ciesielska, A., Przybyłkowski, A., Członkowski, A., & Członkowska, A.
Affiliations
Institute of Psychiatry and Neurology (PL)
Corresponding author
Członkowska, Anna
Venue
International Immunopharmacology
Publisher
Elsevier BV
Published
2004-10
Volume
4
Issue
10-11
Pages
1307-1318
ISSN
1567-5769 (ISSN-L)
OpenAlex
W2059884588
Cited by
117
References
1
Citations by year
2025: 3 · 2024: 5 · 2023: 5 · 2022: 4 · 2021: 4 · 2020: 8 · 2019: 6 · 2018: 4 · 2017: 10 · 2016: 2 · 2015: 8 · 2014: 4 · 2013: 5 · 2012: 8
FWCI
3.87
Type
journal article
Language
en
Open access
closed
Locations
  • International Immunopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
Keywords
dexamethasone, Parkinson's disease, MPTP, neuroprotection, dopaminergic neurons, substantia nigra, striatum, dopamine depletion, neuroinflammation, glial activation, lymphocyte infiltration, dose-dependent effects
MeSH terms
Animals, Anti-Inflammatory Agents, Chromatography, High Pressure Liquid, Corpus Striatum, Dexamethasone, Disease Models, Animal, Dopamine, Dose-Response Relationship, Drug, Inflammation, Male, Mice, Inbred C57BL, Nerve Degeneration, Neurons, Parkinson Disease, Secondary, Blotting, Western, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neuroprotective Agents, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review